Status:

COMPLETED

Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies

Lead Sponsor:

University of Illinois at Chicago

Conditions:

Acute Myeloid Leukemia

Lymphoblastic Leukemia

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

This is a phase I study using Intensity Modulated Total Marrow Irradiation (IM-TMI) in addition to a chemotherapy regimen in preparation for an allogeneic stem cell transplant for advanced hematologic...

Eligibility Criteria

Inclusion

  • Patients with the following diseases:
  • Acute myeloid or lymphoblastic leukemia in first complete remission if poor prognosis documented by failure to response after initial induction chemotherapy, or cytogenetic, or molecular studies.
  • Acute leukemia in greater/equal second remission, or partial remission after chemotherapy.
  • High grade non Hodgkin's or Hodgkin's lymphoma with marrow involvement resistant/ relapsed after second line therapy including high dose chemotherapy and autologous SCT.
  • CML in advanced or blastic phase.
  • Plasma cell leukemia.
  • Age 18-60 years.
  • Karnofsky performance status of 70
  • Adequate cardiac and pulmonary function. Patients with decreased LVEF less than/equal to 40% or DLCO less than/equal to 50% of predicted will require clearance from cardiology or pulmonary services, respectively, prior to enrollment on this protocol.
  • Serum creatinine less than/equal to 1.5 mg/dL or Creatinine Clearance greater than/equal to 50 ml/min .
  • Serum bilirubin 2.0 mg/dl, SGPT less than/equal to 3 times the upper limit of normal

Exclusion

  • Life expectancy is severely limited by concomitant illness.
  • Evidence of chronic active hepatitis or cirrhosis
  • HIV-positive
  • Patient is pregnant
  • Patient or guardian is not able to sign informed consent.

Key Trial Info

Start Date :

September 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2016

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT00988013

Start Date

September 1 2009

End Date

February 1 2016

Last Update

June 14 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Illinois at Chicago

Chicago, Illinois, United States, 60612

Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies | DecenTrialz